Skip to main content
PMVP
NASDAQ Life Sciences

PMV Pharma's Q3 10-Q Clears Going Concern Warning, Cash Runway Now Into Q1 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.25
Mkt Cap
$94.391M
52W Low
$1.02
52W High
$1.91
52W Position info
23% above low
Off High info
35% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PMVP sits 23% above its 52-week low of $1.02 on light trading volume (0.3× avg).

Summary

PMV Pharma's Q3 10-Q shows a $34.4 million net loss that is mostly a non-cash $12.8 million warrant remeasurement, while $108.5 million in cash after the September offering removes the going concern warning and funds operations into Q1 2028.


Key Events · Earnings and Guidance · PMVP

  • Going Concern Warning Removed

    Management concluded there is no longer substantial doubt about the company's ability to continue as a going concern as of this Quarterly Report, reversing the warning in the Q2 2026 10-Q filed August 14, 2026.

  • Cash Runway Extended to Q1 2028

    Cash, cash equivalents and marketable securities totaled $108.5 million at September 30, 2026, which management says funds planned operations into the first quarter of 2028.

  • Loss Widened on Non-Cash Warrant Mark

    Q3 net loss was $34.4 million versus $21.1 million a year earlier, driven by a $12.8 million non-cash change in fair value of the warrant liability and $2.3 million of offering costs allocated to it — no cash outflow and no new dilution.

  • Warrant Liability Grew With Share Price

    The warrant liability rose to $43.6 million at September 30, 2026 from $30.8 million at initial recognition on September 2, 2026, as the common stock price moved from $1.21 to $1.67; a 10% move in the stock price changes the liability by about $5.7 million.


Analysis · PMVP · Life Sciences

The headline loss looks worse than it is: the $34.4 million Q3 net loss versus $21.1 million a year earlier is driven by a $12.8 million non-cash mark-to-market charge on the warrant liability plus $2.3 million of offering costs allocated to that liability — no cash left the company and no new shares were issued for either. The real news is the balance sheet. After the September 2, 2026 offering raised $46.9 million net, cash and securities stood at $108.5 million, and management says that funds operations into the first quarter of 2028 and that substantial doubt about going concern no longer exists — a direct reversal of the warning in the August 14 Q2 10-Q. Operating spend is also falling, with R&D down to $46.1 million for the nine months from $54.1 million. The next hard checkpoint is the rezatapopt NDA submission planned for Q1 2027; the 41,955,000 common warrants carry an exercise-price reset tied to that FDA acceptance announcement, so the warrant liability will keep swinging with the share price and the FDA news.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PMVP was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.4M. The 52-week trading range was $1.02 to $1.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PMVP - Latest Insights

PMVP
Nov 10, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.25 info
Change: -$0.0095 (-0.75%) info
Market Cap: $94.391M info
PMVP
Sep 01, 2026, 6:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $1.25 info
Change: -$0.020 (-2%) info
Market Cap: $94.391M info
PMVP
Sep 01, 2026, 6:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $1.25 info
Change: -$0.020 (-2%) info
Market Cap: $94.391M info
PMVP
Aug 31, 2026, 11:03 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.19
Real-time Price: $1.25 info
Change: +$0.060 (+5%) info
Market Cap: $94.391M info
PMVP
Aug 31, 2026, 4:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $1.25 info
Change: +$0.200 (+19%) info
Market Cap: $94.391M info